Binoy Jani, MD
Ophthalmology · Fredericksburg, VANPI 1548222557
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Bausch & Lomb, A Division Of Bausch Health US, LLC at 56.7% of the total. Reporting peaked in 2019 at $10,771 and has fallen 88.8% since, to $1,201 in 2025. Among ophthalmology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 199 payments — averaging $88.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$10K
- Sun Pharmaceutical Industries Inc.$2K
- Lensar, Inc.$1K
- Alcon$847
- NEW World Medical,inc.$550
- Kala Pharmaceuticals, Inc.$471
- plus $2K from 24 others
What the payments were for
- Consulting fees$6003%
- Speaking & faculty fees$10,50059%
- Travel & lodging$8605%
- Food & beverage$5,68432%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 23 | $10,022 |
| Sun Pharmaceutical Industries Inc. | 26 | $2,373 |
| Lensar, Inc. | 9 | $1,233 |
| Alcon | 28 | $847 |
| NEW World Medical,inc. | 3 | $550 |
| Kala Pharmaceuticals, Inc. | 21 | $471 |
| Harrow Eye, LLC | 5 | $352 |
| Johnson & Johnson Surgical Vision, Inc. | 12 | $277 |
| AbbVie(2 entities) | 10 | $176 |
| Amgen(2 entities) | 7 | $176 |
| Rayner Intraocular Lenses Limited | 5 | $123 |
| Novartis | 6 | $119 |
| Aerie Pharmaceuticals, Inc. | 6 | $97 |
| Sight Sciences, Inc. | 5 | $91 |
| Rxsight Inc | 3 | $90 |
| Ocular Therapeutix, Inc. | 5 | $85 |
| Bausch & Lomb Americas Inc. | 4 | $78 |
| Ivantis, Inc | 1 | $78 |
| Glaukos Corporation | 3 | $74 |
| Coopervision Inc. | 1 | $74 |
| Eyepoint US, Inc. | 3 | $55 |
| Dompe US, Inc. | 2 | $49 |
| Eyevance Pharmaceuticals LLC | 2 | $38 |
| Oasis Medical, Inc. | 2 | $28 |
| Shire North American Group Inc | 2 | $28 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Thea Pharma Inc. | 1 | $17 |
| Johnson & Johnson Vision Care, Inc. | 1 | $15 |
| Omeros Corporation | 1 | $14 |
| Pacira Pharmaceuticals Incorporated | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOTEMAX SM$9,496
- CEQUA$1,800
- LENSAR LASER SYSTEM$1,152
- Ahmed Glaucoma Valve$452
- Kahook Dual Blade$452
- Streamline Surgical System$225
- VEVYE$212
- Unity$180
- NGENUITY$131
- INVELTYS$117
How this compares
$17,663 in reported general payments places this provider in the 95th percentile of 509 ophthalmology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bromfenac Sodium | 288 | $32,000 |
| BesivanceBesifloxacin Hcl | 121 | $25,726 |
| Prednisolone Acetate | 747 | $20,712 |
| ProlensaBromfenac Sodium | 55 | $19,770 |
| LumiganBimatoprost | 35 | $17,867 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 42 | $15,801 |
| IlevroNepafenac | 33 | $12,433 |
| MoxifloxacinMoxifloxacin Hcl | 678 | $12,308 |
| VyzultaLatanoprostene Bunod | 12 | $10,545 |
| RhopressaNetarsudil Mesylate | 20 | $9,331 |
| Brimonidine Tartrate | 67 | $8,855 |
| Alphagan PBrimonidine Tartrate | 12 | $6,529 |
| BromsiteBromfenac Sodium | 21 | $5,437 |
| Lotemax SmLoteprednol Etabonate | 21 | $5,172 |
| Latanoprost | 372 | $5,011 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCBesivance, Prolensa, Lotemax Sm | $10,022 | $50,668197 claims |
| AbbVieLumigan, Alphagan P | $176 | $24,39647 claims |
| AlconSimbrinza | $847 | $15,80142 claims |
| NovartisIlevro | $119 | $12,43333 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $78 | $10,54512 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $97 | $9,33120 claims |
| Sun Pharmaceutical Industries Inc.Bromsite | $2,373 | $5,43721 claims |
| Kala Pharmaceuticals, Inc.Inveltys | $471 | $4,32615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 509 ophthalmology providers in Virginia.
Other ophthalmology in Fredericksburg
- James SavageFredericksburg$25K
- Ethnie JonesRichmond$2M
- Elizabeth Yeu-LinNorfolk$1.7M
- John SheppardNorfolk$1.1M
- Constance OkekeNorfolk$800K
- Marc OdrichCharlottesville$497K
- Jayakrishna AmbatiCharlottesville$116K
- Thomas JolyNorfolk$95K
- Stephen ScoperNorfolk$88K
- Leonard RappaportPortsmouth$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.